<DOC>
	<DOCNO>NCT01940978</DOCNO>
	<brief_summary>Lack appetite weight loss common side effect ADHD therapy amphetamine methylphenidate . Lack sufficient food intake show negative effect weight height well learn memory . There current treatment prevent loss appetite except discontinuation reduction methylphenidate . Discontinuation reduction drug cause return ADHD symptom . The purpose study compare effect , good and/or bad , two dos drug , cyproheptadine , v placebo find cyproheptadine prevents appetite suppression associate methylphenidate .</brief_summary>
	<brief_title>A Study Combination Therapy Children With ADHD</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Problem Behavior</mesh_term>
	<mesh_term>Attention Deficit Disruptive Behavior Disorders</mesh_term>
	<mesh_term>Neurodevelopmental Disorders</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<mesh_term>Cyproheptadine</mesh_term>
	<criteria>The subject subject 's parent speak English Child adolescent patient , male female outpatient , least 6 year age , must yet reach 13th birthday prior Visit 1 , inform consent obtain Patients must meet Diagnostic Statistical Manual Mental Disorders Fourth Edition ( DSMIV ) diagnostic criterion ADHD ( subtype ) score least 1.5 standard deviation age norm diagnostic subtype use publish norm Swanson , Nolan Pelham Questionnaire : AttentionDeficit/Hyperactivity Disorder Subscale ( SNAPIV ADHD Subscale ) score Visit 1 2 Laboratory result , include serum chemistry , hematology , urinalysis , must show clinically significant abnormality ( clinically significant define laboratory value require acute medical intervention , indicate serious medical illness , require medical evaluation judgment investigator ) Patients parent judged investigator reliable keep appointment clinic visit test , include venipuncture , examination require protocol . Patient stimulant least 2 week . Patients document history Bipolar I II disorder , history psychosis . Diabetic patient patient chronic steroid . Patients history seizure disorder ( febrile seizure ) patient take ( currently take ) anticonvulsant seizure control eligible participate Patients serious suicidal risk define 1 ) suicidal ideation endorse item 4 5 CSSRS within past year , 2 ) suicidal behavior detect CSSRS past two year ; 3 ) psychiatric interview examination Patients significant cardiovascular disease condition could aggravate increased heart rate increase blood pressure Patients medical condition would increase sympathetic nervous system activity markedly ( example , catecholaminesecreting neural tumor ) , take medication daily basis ( example , albuterol , inhalation aerosol , pseudoephedrine ) , sympathomimetic activity . Such medication take asneeded basis Presence contraindication methylphenidate cyproheptadine hydrochloride Patients prior serious adverse reaction stimulant . Parental ( immediate ) family history substance abuse</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Methamphetamine</keyword>
	<keyword>Methylphenidate</keyword>
	<keyword>ADHD</keyword>
</DOC>